infiltrate in the upper and lower plexus, mixed with many neutrophils, nuclear dust and some eosinophils as well as extravasal erythrocytes. Direct immunofluorescence revealed C3 complement and fibrinogen deposits around the vessels. Based on these findings, a histological diagnosis of leukocytoclastic vasculitis was made. Erlotinib was discontinued and oral prednisolone treatment (40 mg for 3 days and subsequently 30-20-10 mg from day 4 to 6) was started in combination with topical anti-infective therapy. The lesions cleared within 6 weeks without recurrence.
The second patient, a 70-year-old woman with metastatic pancreatic adenocarcinoma, started treatment with gemcitabine and erlotinib in February 2007 [3] . After 2 weeks on erlotinib (150 mg daily), an acneiform skin rash (limited to seborrheic areas like face and upper trunk) appeared. Another 3 weeks later, a different type of rash developed on both thighs, clinically indicative of allergic vasculitis ( Figure 1B ). Skin biopsy revealed leukocytoclastic vasculitis. Erlotinib was discontinued and the patient received the same treatment regimen with steroids as described above combined with topical therapy. The lesions cleared within 5 weeks without recurrence. Both patients did not show any sings of systemic vasculitis by clinical and laboratory examinations. An allergy work-up was offered, but both patients refused further diagnostic procedures.
Paraneoplastic vasculitis is a known phenomenon in patients with hematological and solid malignancies [4, 5] . Interestingly, both episodes of cutaneous leukocytoclastic vasculitis in our patients did not occur within (or even before) the first diagnosis of malignant disease, but during treatment with the anti-EGFR tyrosine kinase inhibitor erlotinib. Cutaneous drug eruptions develop frequently in patients receiving EGFRtargeting drugs [1] , but we are unaware of any report on cutaneous vasculitis syndromes in association with erlotinib therapy to date. Based on the molecular mechanisms of EGFR-targeting agents and the observed correlation in time, a causal relationship between the leukocytoclastic vasculitis and erlotinib treatment appears probable in both patients. We therefore strongly recommend further preclinical and clinical investigation of this syndrome in order to improve the classification, diagnosis and treatment of erlotinib-associated skin reactions. 
